Roche wants certification of skin cancer drug ? BusinessWeek ...

NEW YORK

Swiss pharmaceutical giant Roche and drug developer Curis Inc. said Monday that Roche, the Food and Drug Administration asked the vismodegib drug as a treatment for the most common form of skin cancer to be approved.

Roche?s Genentech unit for marketing approval of vismodegib filed as a treatment for advanced basal cell carcinoma. Curis said about 2 million cases of basal cell carcinoma in the United States are diagnosed annually, and the disease is curable in the rule if it only affects a small area of ??skin. Vismodegib is for patients who have not been treated or whose cancer has progressed despite treatment determined. It is an oral drug that is one way in more than 90 percent of the cases of the disease.

blocks participating in studies, the drug shrank tumors and significantly reduced lesions in 43 percent of patients with locally advanced cancer and 30 percent of patients whose cancer had metastasized. The company said the most common side effects of treatment with vismodegib were muscle cramps, hair loss, changes in taste, weight loss, fatigue, nausea, anorexia and diarrhea.

Vismodegib Genentech is the second bill this year for a skin-cancer treatment. If the FDA accepts the submission, Genentech will pay Curis $ 8,000,000. Genentech is also preparing for the approval of the European Union in vismodegib file. Vismodegib was Genentech, which was discovered in San Francisco. Curis, of Lexington, Massachusetts, is a drug development company that helped in preclinical studies. Curis shares up 7 cents, or 2.4 percent to $ 2.98 in morning trading.

Related Post for Roche wants certification of skin cancer drug ? BusinessWeek

Source: http://blamecancer.org/skin-cancer/roche-wants-certification-of-skin-cancer-drug-businessweek.html

new jersey map tornado okami okami rainbow rainbow doctor who